BIOSGN.ST
Price:
$50.2
Market Cap:
$117.88M
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Industry
Biotechnology
IPO Date
2021-06-24
Stock Exchange
STO
Ticker
BIOSGN.ST
According to Biosergen AB’s latest financial reports and current stock price. The company's current PE Ratio is -25.10. This represents a change of 577.51% compared to the average of -3.70 of the last 4 quarters.
The mean historical PE Ratio of Biosergen AB over the last ten years is -52.40. The current -25.10 PE Ratio has changed 4.69% with respect to the historical average. Over the past ten years (40 quarters), BIOSGN.ST's PE Ratio was at its highest in in the March 2024 quarter at -0.79. The PE Ratio was at its lowest in in the March 2022 quarter at -11.79.
Average
-52.40
Median
-7.54
Minimum
-269.03
Maximum
-1.44
Discovering the peaks and valleys of Biosergen AB PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 360.92%
Maximum Annual PE Ratio = -1.44
Minimum Annual Increase = -89.89%
Minimum Annual PE Ratio = -269.03
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -6.62 | 360.92% |
| 2023 | -1.44 | -11.67% |
| 2022 | -1.63 | -80.74% |
| 2021 | -8.45 | -68.95% |
| 2020 | -27.20 | -89.89% |
The current PE Ratio of Biosergen AB (BIOSGN.ST) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.23
5-year avg
-9.07
10-year avg
-52.40
Biosergen AB’s PE Ratio is less than Nanologica AB (publ) (-1.58), less than Biovica International AB (publ) (-0.66), less than Active Biotech AB (publ) (-2.05), less than NextCell Pharma AB (-2.30), less than Arcoma AB (23.87), less than Pila Pharma AB (publ) (-5.64), less than Scandinavian ChemoTech AB (publ) (-10.01), less than Xbrane Biopharma AB (publ) (1.93), less than Sprint Bioscience AB (publ) (-6.27), less than SciBase Holding AB (publ) (-1.45),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.58 | $75.11M | |
| -0.66 | $114.88M | |
| -2.05 | $78.73M | |
| -2.30 | $81.87M | |
| 23.87 | $103.88M | |
| -5.64 | $98.48M | |
| -10.01 | $86.97M | |
| 1.93 | $115.41M | |
| -6.27 | $160.91M | |
| -1.45 | $139.05M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biosergen AB using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biosergen AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biosergen AB's PE Ratio?
How is the PE Ratio calculated for Biosergen AB (BIOSGN.ST)?
What is the highest PE Ratio for Biosergen AB (BIOSGN.ST)?
What is the 3-year average PE Ratio for Biosergen AB (BIOSGN.ST)?
What is the 5-year average PE Ratio for Biosergen AB (BIOSGN.ST)?
How does the current PE Ratio for Biosergen AB (BIOSGN.ST) compare to its historical average?